Is the increase in eltrombopag dose cause of myocardial infarction?

Özet

Immune thrombocytopenia (ITP) is an acquired disorder caused by immune-mediated attack, enhanced clearance, and insufficient compensatory production of platelets. Historically, ITP treatment strategies have suppressed platelet destruction with glucocorticoids, intravenous immune globulin (IVIG), cytotoxic agents, and splenectomy (1). Eltrombopag is an oral nonpeptide thrombopoietin receptor agonist (TPO-RA) approved for use in several countries for the treatment of ITP with insufficient response to corticosteroids, immunoglobulins, or splenectomy. In this study, we present a patient with ITP who developed recurrent myocardial infarction and intense thrombus in the stent after increasing the eltrombopag dose.